|
|
Article: Saizen, Serono's Human Growth Hormone (rDNA Origin) for Children with Growth Hormone Deficiency, Receives FDA Clearance to Market
- Article from:
- PR Newswire
- Article date:
- October 15, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Serono Laboratories Achieves Historic Milestone with the FDA's Third Favorable
Decision for the Company's Biopharmaceutical Products
NORWELL, Mass., Oct. 15 /PRNewswire/ -- Serono Laboratories, Inc., today announced that the U.S. Food and Drug Administration (FDA) authorized Saizen(R) [somatropin (rDNA origin) for injection] for marketing in the United States for the treatment of children with growth failure due to inadequate levels of growth hormone. This is the third favorable FDA decision for Serono, rendered by the Agency within just six weeks, and marks an unprecedented achievement for the company.
On August 23, the FDA ...